Without a specific catalyst driving headlines, STERIS (STE) still attracts attention from investors reviewing its recent share performance and financial profile, particularly given its infection prevention focus across healthcare, life sciences, and sterilization services.
See our latest analysis for STERIS.
Recent share price returns for STERIS have been mixed, with the stock up 1.63% over the last day but down 14.39% year to date. The 1 year total shareholder return declined 6.13%, suggesting momentum has been softening despite its established position in healthcare and life sciences services.
If you are comparing STERIS with other healthcare related opportunities, it can be useful to widen the lens using a screener focused on similar themes such as 40 healthcare AI stocks
STERIS has pulled back this year even as revenue and net income growth remain positive. The question is whether that recent weakness already reflects the risks or whether patience could offer a more attractive entry as valuation comes into focus.
Most Popular Narrative: 16.7% Undervalued
At the latest close of $214.07, the most followed narrative for STERIS points to a fair value of about $256.86, framing the stock as modestly undervalued based on detailed long term assumptions.
Continued expansion of STERIS's consumables and services segments, with high recurring revenue and margin visibility, positions the company to benefit from increasing healthcare expenditures and adoption of best-practice infection control standards, supporting both revenue and margin expansion.
This raises questions about the basis for optimism on recurring earnings. The narrative leans heavily on steady revenue compounding, margin lift and a richer earnings multiple in future years. The key issue is how those assumptions compare with your own expectations.
Result: Fair Value of $256.86 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, investors weighing the STERIS story also need to factor in tariff related cost pressure and the possibility that acquisition led growth falls short of expectations.
Find out about the key risks to this STERIS narrative.
Another View: What STERIS’s P/E Says About Valuation Risk
While the DCF based fair value for STERIS suggests the stock trades at a discount, the P/E picture is less clear cut. At 26.7x earnings, STERIS trades in line with the US Medical Equipment industry average of 26.7x, yet above its own fair ratio of 24.8x. This difference hints at some valuation risk if earnings or sentiment soften.
For investors comparing methods, this raises a practical question: should more weight be placed on the DCF discount, or on the possibility that the market gradually gravitates toward that lower fair ratio on earnings?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Given the mixed signals around STERIS and its valuation, it makes sense to check the underlying data yourself, weigh both the concerns and potential upsides, and then review the 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond STERIS?
If STERIS has sharpened your interest in healthcare and quality businesses, do not stop here. Widen your watchlist with fresh ideas from powerful stock screeners.
- Target income potential with stocks that combine robust yields and defensive characteristics by reviewing 9 dividend fortresses.
- Hunt for quality companies trading below what their fundamentals suggest by scanning the 49 high quality undervalued stocks.
- Focus on financial strength first and filter for companies with resilient balance sheets using the solid balance sheet and fundamentals stocks screener (49 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com